ATE401333T1 - 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors - Google Patents
1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptorsInfo
- Publication number
- ATE401333T1 ATE401333T1 AT02742943T AT02742943T ATE401333T1 AT E401333 T1 ATE401333 T1 AT E401333T1 AT 02742943 T AT02742943 T AT 02742943T AT 02742943 T AT02742943 T AT 02742943T AT E401333 T1 ATE401333 T1 AT E401333T1
- Authority
- AT
- Austria
- Prior art keywords
- oxa
- derivatives
- receptor antagonists
- neurokinin receptor
- neurokinin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01111644 | 2001-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401333T1 true ATE401333T1 (de) | 2008-08-15 |
Family
ID=8177412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02742943T ATE401333T1 (de) | 2001-05-14 | 2002-05-06 | 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6599900B2 (de) |
| EP (1) | EP1390372B1 (de) |
| JP (1) | JP4056887B2 (de) |
| KR (1) | KR100618063B1 (de) |
| CN (1) | CN1264847C (de) |
| AR (1) | AR033631A1 (de) |
| AT (1) | ATE401333T1 (de) |
| AU (1) | AU2002342238B2 (de) |
| BR (1) | BR0209604A (de) |
| CA (1) | CA2447329C (de) |
| DE (1) | DE60227657D1 (de) |
| DK (1) | DK1390372T3 (de) |
| ES (1) | ES2310206T3 (de) |
| MX (1) | MXPA03010321A (de) |
| PT (1) | PT1390372E (de) |
| WO (1) | WO2002092604A1 (de) |
| ZA (1) | ZA200308535B (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005211499A1 (en) | 2004-02-10 | 2005-08-18 | F. Hoffmann-La Roche Ag | Chemokine CCR5 receptor modulators |
| MX2007009571A (es) | 2005-02-25 | 2007-09-21 | Hoffmann La Roche | Tabletas con dispersion mejorada de la sustancia del farmaco. |
| NZ556629A (en) | 2005-03-03 | 2010-04-30 | Janssen Pharmaceutica Nv | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists |
| CA2599186C (en) | 2005-03-08 | 2014-12-09 | Janssen Pharmaceutica N.V. | Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists |
| US7470684B2 (en) | 2007-01-03 | 2008-12-30 | Hoffmann-La Roche Inc. | Spiropiperidine derivatives as NK3 antagonists |
| EP2117538A1 (de) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmazeutische zusammensetzungen mit 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| WO2008119663A1 (en) | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| JP6832914B2 (ja) | 2015-07-31 | 2021-02-24 | ファイザー・インク | Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体 |
| SG11201906417RA (en) | 2017-01-20 | 2019-08-27 | Pfizer | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors |
| BR112019014099A2 (pt) | 2017-01-23 | 2020-02-11 | Pfizer Inc. | Compostos espiro-heterocíclico como inibidores de magl |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2131021B (en) * | 1982-11-24 | 1985-12-18 | Erba Farmitalia | Antipsychotic benzoxazines |
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| EP0854869B1 (de) * | 1995-09-29 | 2004-08-25 | Eli Lilly And Company | Spiro verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation |
-
2002
- 2002-05-06 CN CNB028094735A patent/CN1264847C/zh not_active Expired - Fee Related
- 2002-05-06 DK DK02742943T patent/DK1390372T3/da active
- 2002-05-06 PT PT02742943T patent/PT1390372E/pt unknown
- 2002-05-06 AU AU2002342238A patent/AU2002342238B2/en not_active Ceased
- 2002-05-06 EP EP02742943A patent/EP1390372B1/de not_active Expired - Lifetime
- 2002-05-06 JP JP2002589488A patent/JP4056887B2/ja not_active Expired - Fee Related
- 2002-05-06 ES ES02742943T patent/ES2310206T3/es not_active Expired - Lifetime
- 2002-05-06 KR KR1020037014713A patent/KR100618063B1/ko not_active IP Right Cessation
- 2002-05-06 DE DE60227657T patent/DE60227657D1/de not_active Expired - Lifetime
- 2002-05-06 CA CA002447329A patent/CA2447329C/en not_active Expired - Fee Related
- 2002-05-06 WO PCT/EP2002/004935 patent/WO2002092604A1/en active IP Right Grant
- 2002-05-06 MX MXPA03010321A patent/MXPA03010321A/es active IP Right Grant
- 2002-05-06 AT AT02742943T patent/ATE401333T1/de not_active IP Right Cessation
- 2002-05-06 BR BR0209604-8A patent/BR0209604A/pt not_active IP Right Cessation
- 2002-05-10 AR ARP020101705A patent/AR033631A1/es unknown
- 2002-05-10 US US10/143,431 patent/US6599900B2/en not_active Expired - Fee Related
-
2003
- 2003-10-31 ZA ZA200308535A patent/ZA200308535B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002342238B2 (en) | 2007-01-25 |
| PT1390372E (pt) | 2008-08-25 |
| CN1507449A (zh) | 2004-06-23 |
| CN1264847C (zh) | 2006-07-19 |
| CA2447329C (en) | 2009-07-28 |
| EP1390372B1 (de) | 2008-07-16 |
| DE60227657D1 (de) | 2008-08-28 |
| KR100618063B1 (ko) | 2006-08-30 |
| US6599900B2 (en) | 2003-07-29 |
| MXPA03010321A (es) | 2004-02-17 |
| AR033631A1 (es) | 2003-12-26 |
| US20030004163A1 (en) | 2003-01-02 |
| ES2310206T3 (es) | 2009-01-01 |
| DK1390372T3 (da) | 2008-09-15 |
| CA2447329A1 (en) | 2002-11-21 |
| EP1390372A1 (de) | 2004-02-25 |
| JP2004534758A (ja) | 2004-11-18 |
| BR0209604A (pt) | 2004-03-23 |
| WO2002092604A1 (en) | 2002-11-21 |
| JP4056887B2 (ja) | 2008-03-05 |
| KR20030094405A (ko) | 2003-12-11 |
| ZA200308535B (en) | 2005-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60325493D1 (de) | Substituierte 1,4-dipiperidin-4-yl-piperazinderivate und deren verwendung als neurokininantagonisten | |
| DE602005011593D1 (de) | Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten | |
| ATE381565T1 (de) | 1,3,8-triaza-spiro 4,5 decan-4-onderivative als neurokininrezeptorantagonisten | |
| DE50213525D1 (de) | Substituierte 2, 6-diamino-3, 5-dicyano-4-aryl-pyridine und ihre verwendung als adenosinrezeptor selektive liganden | |
| DE50208895D1 (de) | Substituierte 2-thio-3, 5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden | |
| DE50210986D1 (de) | Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden | |
| DE60113719D1 (de) | Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten | |
| NO20052496D0 (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. | |
| DE60201437D1 (de) | 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten | |
| DE50204037D1 (de) | Substituierte 1-oxa-2,8-diaza-spiro[4,5]dec-2-en-derivate als arzneimittel gegen schmerz | |
| DE60112607T2 (de) | 3-arylindolderivate und deren verwendung als cb2-rezeptoragonisten | |
| DE60336266D1 (de) | Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten | |
| DE60106607D1 (de) | Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten | |
| DE602005007002D1 (de) | Substituierte 4-alkyl- und 4-alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten | |
| DE60114413D1 (de) | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten | |
| ATE432282T1 (de) | 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten | |
| ATE401333T1 (de) | 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors | |
| DE60305026D1 (de) | 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten | |
| HK1042699A1 (en) | N-triazolylmethyl-piperazine derivatives as neurokinin receptor antagonists. | |
| DE60126614D1 (de) | 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten | |
| ATE329908T1 (de) | Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten | |
| NO20053598D0 (no) | Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister. | |
| ATE353325T1 (de) | 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-metho y-phenoxy)-2-pyridyl-pyrimidin derivate, deren herstellung und deren verwendung als endothelin rezeptor antagonisten | |
| ATE389659T1 (de) | Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors | |
| ATE484503T1 (de) | 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1390372 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |